Antimicrobial activity of two antitumour agents and ribonucleotide reductase inhibitors, pyridine-2-carboxaldehyde thiosemicarbazone and the acetate form of its copper(II) chelate

Zeitschrift fur Naturforschung - Section C Journal of Biosciences

Volumn 62, Issue 7-8, 2007, Pages 498-506

  Elo, Hannu ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Antibacterial agents; Antifungal agents; Antimicrobial metal complex

Indexed keywords

ASPERGILLUS NIGER; BACILLUS (BACTERIUM); BACILLUS CEREUS; BACILLUS SP.; BACTERIA (MICROORGANISMS); CANDIDA ALBICANS; ESCHERICHIA COLI; LACTOCOCCUS LACTIS; PSEUDOMONAS AERUGINOSA; SACCHAROMYCES CEREVISIAE; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS;

EID: 34548660202     PISSN: 09395075     EISSN: None     Source Type: Journal    
DOI: 10.1515/znc-2007-7-807     Document Type: Article

References (43)

1. Agrawal K.C. and Sartorelli A.C. (1975), α-(N)-Heterocyclic carboxaldehyde thiosemicarbazones. In: Handbuch der Experimentellen Pharmakologie - Handbook of Experimental Pharmacology, Vol. 38/2 (Sartorelli A. C. and Johns D. G., eds.) Springer-Verlag, Berlin, pp. 793-807.
2. Antholine W. E., Knight J. M., and Petering D. H. (1976), Inhibition of tumor cell transplantability by iron and copper complexes of 5-substituted 2-formylpyridine thiosemicarbazones. J. Med. Chem. 19, 339-341.
3. Bell C. F. and Theocharis C. R. (1987), Structure of the antitumor agent di-μ-acetato-(O)-bis[(2-pyridinecarbaldehyde thiosemicarbazonato)copper(II)]. Acta Cryst. C 43, 26-29.
4. Bozdogan B., Esel D., Whitener C., Browne F. A., and Appelbaum P. C. (2003), Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center. J. Antimicr. Chemother. 52, 864-868.
5. Brockman R. W., Thomson J. R., Bell M. J., and Skipper H. E. (1956), Observations on the antileukemic activity of pyridine-2-carboxaldehyde thiosemicarbazone and thiocarbohydrazone. Cancer Res. 16, 167-170.
6. Centers for Disease Control and Prevention (2002), Staphylococcus aureus resistant to vancomycin - Unites States, 2002. Morb. Mortal. Wkly. Rep. 51, 565-567.
7. Cetinkaya Y., Falk P., and Mayhall C. G. (2000), Vancomycin-resistant enterococci. Clin. Microbiol. Rev. 13, 686-707.
8. Chattopadhyay S. K., Hossain M., Ghosh S., and Guha A. (1990), Ligational behavior of two biologically active nitrogen-sulfur donors towards cobalt(III), iron(III), iron(II) and rhodium(III). Transition Met. Chem. 15, 473-477.
9. Cleare M. J. and Hydes P. C. (1980), Antitumor properties of metal complexes. In: Metal Ions in Biological Systems, Vol. 11 (Sigel H., ed.). Marcel Dekker, Inc., New York, pp. 1-62.
10. Cory J. G., Cory A. H., Rappa G., Lorico A., Liu M. C., Lin T. S., and Sartorelli A. C. (1994), Inhibitors of ribonucleotide reductase. Comparative effects of amino- and hydroxy-substituted pyridine-2-carboxaldehyde thiosemicarbazones. Biochem. Pharmacol. 48, 335-344.
11. Cory J. G., Cory A. H., Rappa G., Lorico A., Liu M. C., Lin T. S., and Sartorelli A. C. (1995), Structure-function relationships for a new series of pyridine-2-carboxaldehyde thiosemicarbazones on ribonucleotide reductase activity and tumor cell growth in culture and in vivo. Adv. Enz. Regul. 35, 55-68.
12. Cunha B. A. (2005), Methicillin-resistant Staphylococcus aureus: clinical manifestations and antimicrobial therapy. Clin. Microbiol. Infect. 11, 33-34.
13. Elo H. (1987a), Reaction of the antiproliferative and antineoplastic agent trans-bis(salicylaldoximato)copper(II) and related chelates with glutathione and cysteine. Correlation between reactivity and biological activity. Inorg. Chim. Acta 136, L33-L35.
14. Elo H. (1987b), An antiproliferative salicylaldoximato type copper(II) chelate as an enhancer of the cytotoxicity of murine spleen cells to tumor cells in vitro. Cancer Lett. 36, 333-339.
15. Elo H. (2004a), Uniform potent activity of the antiproliferative metal chelate trans-bis(resorcylaldoximato)-copper(II) against a large panel of human tumor cell lines in vitro. Chemotherapy 50, 229-233.
16. Elo H. (2004b), The antiproliferative agents trans-bis(resorcylaldoximato)copper(II) and trans-bis(2,3,4- trihydroxybenzaldoximato)copper(II) and cytopathic effects of HIV. Z. Naturforsch. 59c, 609-611.
17. Elo H. O. and Lumme P. O. (1985), Antitumor activity of trans-bis(sahcylaldoximato)copper(II): a novel antiproliferative metal complex. Cancer Treat. Rep. 69, 1021-1022.
18. Elo H. and Lumme P. (1986), Antiproliferative activity of derivatives of trans-bis(sahcylaldoximato)copper(II) in vitro. Some in vivo properties of the parent compound. Z. Naturforsch. 41c, 951-955.
19. Elo H. and Lumme P. (1987), Trans-bis(salicylaldoximato)copper(II) and its derivatives as antiproliferative and antineoplastic agents: a review. Inorg. Chim. Acta 136, 149-153.
20. Elo H. and Sunila I. (1987), Unusual organ distribution of chelated copper in rats. Naturwissenschaften 74, 245-246.
21. Elo H., Sunila I., and Lumme P. (1987), Studies on the acute toxicity of the antineoplastic metal chelate trans-bis(salicylaldoximato)copper(II) in rats. Inorg. Chim. Acta 136, 61-63.
22. Elo H., Matikainen J., and Pelttari E. (2007), Potent activity of the lichen antibiotic (+)-usnic acid against clinical isolates of vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus. Naturwissenschaften 94, 465-468.
23. Feun L., Modiano M., King L., Mao J., Marini A., Savaraj N., Plezia P., Almassian B., Colacino E., Fischer J., and MacDonald S. (2002), Phase I and pharmacokinetic study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) using a single intravenous dose schedule. Cancer Chemother. Pharmacol. 50, 223-229.
24. Hanaki H., Yamaguchi Y., Yanagisawa C., Uehara K., Matsui H., Yamaguchi Y., Hososaka Y., Barada K., Sakai F., Itabashi Y., Ikeda S., Atsuda K., Tanaka H., Inamatsu T., Nagayama A., and Sunakawa K. (2005), Investigation of beta-lactam antibiotic-induced vancomycin-resistant MRSA (BIVR). J. Infect. Chemother. 11, 104-106.
25. Hemmerich P., Prijs B., and Erlenmeyer H. (1958), Pyridyl-1,3,4- thiadiazole; eine neue Variante der Thiadiazol-Synthese. Helv. Chim. Acta 40, 2058-2065.
26. Hochman H. I., Agrawal K. C., and Sartorelli A. C. (1972a), Biochemical studies of the effects of 1-formylisoquinoline thiosemicarbazone (IQ-1) in Escherichia coli B. Biochem. Pharmacol. 21, 3213-3221.
27. Hochman H. I., Agrawal K. C., and Sartorelli A. C. (1972b), Localization in Escherichia coli B of two enzymic sites of action by 1-formylisoquinoline thiosemicarbazone (IQ-1) on ribonucleic acid biosynthetic pathways. Biochem. Pharmacol. 21, 3223-3233.
28. Hsueh P.-R., Chen W.H., Teng L.-J., and Luh K.-T. (2005), Nosocomial infections due to methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci at a university hospital in Taiwan from 1991 to 2003; resistance trends, antibiotic usage and in vitro activities of newer antimicrobial agents. Int. J. Antimicr. Agents 26, 43-49.
29. Li J., Zheng L. M., King I., Doyle T. W., and Chen S. H. (2001), Syntheses and antitumor activities of potent inhibitors of ribonucleotide reductase: 3-amino-4-methylpyridine-2-carboxaldehyde-thiosemicarbazone (3-AMP), 3-amino-pyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) and its water-soluble prodrugs. Curr. Med. Chem. 8, 121-133.
30. Maiti A., Guha A. K., and Ghosh S. (1988), Ligational behavior of two biologically active N-S donors toward oxovanadium(IV) ion and potentiation of their antibacterial activities by chelation to metal ions. Part III. J. Inorg. Biochem. 33, 57-65.
31. Murren J., Modiano M., Clairmont C., Lambert P., Savaraj N, Doyle T., and Sznol M. (2003), Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors. Clin. Cancer Res. 9, 4092-4100.
32. Pelttari E., Matikainen J., and Elo H. (2002), Antimicrobial activity of the marine alkaloids haminol and pulo'upone and related compounds. Z. Naturforsch. 57c, 548-552.
33. Pelttari E., Karhumäki E., Langshaw J., Peräkylä H., and Elo H. (2007a), Antimicrobial properties of substituted salicylaldehydes and related compounds. Z. Naturforsch. 62c, 487-497.
34. Pelttari E., Karhumäki E., Langshaw J., and Elo H. (2007b), Carbohydrazones of substituted salicylaldehydes as potential lead compounds for the development of narrow-spectrum antimicrobials. Z. Naturforsch. 62c, 483-486.
35. Petering D. H. (1980), Carcinostatic copper complexes. In: Metal Ions in Biological Systems, Vol. 11 (Sigel H., ed.). Marcel Dekker, Inc., New York, pp. 197-229.
36. Rosenberg B. (1973), Platinum coordination complexes in cancer chemotherapy. Naturwissenschaften 60, 399-406.
37. Rosenberg B. (1980), Clinical aspects of platinum anticancer drugs. In: Metal Ions in Biological Systems, Vol. 11 (Sigel H., ed.). Marcel Dekker, Inc., New York, pp. 127-196.
38. Rosenberg B., Van Camp L., and Krigas T. (1965), Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature 205, 698-699.
39. Rosenberg B., Van Camp L., Trosko J. E., and Mansour V. H. (1969), Platinum compounds: a new class of potent antitumour agents. Nature 222, 385-386.
40. Saryan L. A., Ankel E., Krishnamurti C., and Petering D. H. (1979), Comparative cytotoxic and biochemical effects of ligands and metal complexes of α-N-heterocyclic carboxaldehyde thiosemicarbazones. J. Med. Chem. 22, 1218-1221.
41. Shao J., Zhou B., Chu B., and Yen Y. (2006), Ribonucleotide reductase inhibitors and future drug design. Curr. Cancer Drug Targets 6, 409-431.
42. Snyder R. D. (1984), Inhibitors of ribonucleotide reductase alter DNA repair in human fibroblasts through specific depletion of purine deoxynucleotide triphosphatases. Cell Biol. Toxicol. 1, 81-94.
43. Weigelt J., Kaafarani H. M. A., Itani K. M. F., and Swanson R. N. (2004), Linezolid eradicates MRSA better than vancomycin from surgical-site infections. Am. J. Surg. 188, 760-766.